The pharmaceutical major — Sun Pharma on Friday reported in-line first-quarter results, as expected by the majority of the brokerages, it posted a net profit of Rs 1,444.17 crore for the June-ended quarter of the financial year 2021-22, as compared to a net loss of Rs 1,655.6 crore in the same period last year. 

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Meanwhile, the company in its filing to exchanges also reported a 28 per cent jump in consolidated revenue from operations to Rs 9,718.74 crore in Q1 FY22, as against Rs 7,585.25 crore in Q1 FY20.

Amid in-line Q1 numbers, the shares of Sun Pharma spurted 11 per cent, and touched a new life high to Rs 780 per share on the BSE intraday trade, while it ended over 10 per cent higher to Rs 774 per share on the BSE, as compared to 0.13 per cent decline in the S&P BSE Sensex.

 

“We witnessed a strong Q1, driven by a combination of robust core business growth, low base and some sale of Covid products”, says Sun Pharma Managing Director Dilip Shanghvi. “India business continues to do well while our global specialty revenues have grown over Q4. We are happy with Ilumya’s performance which has grown both YoY and sequentially.” 

 

“The company has repaid debt of about US$ 185 million in Q1FY22 compared to the debt as of March 31, 2021,” Sun Pharma said in its stamtement.

 

Over the last 5 quarters, the Company has repaid debt of about US$ 765 million.

 

Other important Highlights of Q1FY22 consolidated financials

 

India sales at Rs. 33,084 million, up 39% compared to Q1 last year

 

US finished dosage sales at US$ 380 million, growth of 35% over same quarter last year

 

Emerging Markets sales at US$ 218 million, up by 25% over Q1 last year

 

R&D investments at Rs. 5,926 million compared to Rs. 4,206 million for Q1FY21.

 

EBITDA at Rs. 27,718 million, up by 59% over Q1 last year, with resulting EBITDA margin of 28.7%